All lobbying filings

AVIVA STRATEGIES (FKA MGB CONSULTING)

AVIVA STRATEGIES (FKA MGB CONSULTING) filed a Q2 report for ENDEAVOR BIOMEDICINES on July 17, 2026, reporting $51,000 in lobbying income.

Lobbying for ENDEAVOR BIOMEDICINES · Biotechnology & therapeutics

All filings by AVIVA STRATEGIES (FKA MGB CONSULTING) · Everything ENDEAVOR BIOMEDICINES has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 17, 2026

Income

$51,000

What the client paid this registrant for the period.

Client based in

California

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

FAIR Act HR 7953 FDA Modernization

Bills named in this filing 1

H.R. 7953
FAIR ACT

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.